The Technical Analyst
AcelRx Pharmaceuticals [ACRX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
AcelRx Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
7.50% $0.860
America/New_York / 9 jan 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 14.58 mill |
| EPS: | -2.75 |
| P/E: | -0.313 |
| Earnings Date: | Mar 27, 2024 |
| SharesOutstanding: | 16.95 mill |
| Avg Daily Volume: | 0.139 mill |
| RATING 2024-01-16 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.313 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.313 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.848 - 0.996 ( +/- 8.03%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-15 | Nantahala Capital Management, Llc | Buy | 0 | Common Stock |
| 2023-07-20 | Nantahala Capital Management, Llc | Buy | 2 205 883 | 2023 Series A Warrants |
| 2023-07-20 | Nantahala Capital Management, Llc | Buy | 2 205 883 | 2023 Series B Warrants |
| 2023-07-20 | Nantahala Capital Management, Llc | Buy | 750 883 | 2023 Pre-Funded Warrants |
| 2024-03-15 | Nantahala Capital Management, Llc | Buy | 755 000 | Call Option (Right to Buy) |
| INSIDER POWER |
|---|
| 83.13 |
| Last 92 transactions |
| Buy: 3 436 001 | Sell: 171 828 |
Forecast:
01:40 - $0.897
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.860 (7.50% ) |
| Volume | 0.241 mill |
| Avg. Vol. | 0.139 mill |
| % of Avg. Vol | 173.60 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ACRX
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Last 10 Buy Signals
Latest Press Releases
2024-01-09 09:05:00 - Press Release
Acelrx Announces Rebranding With Name Change To Talphera, Inc.
Name change to "talphera" reflects a new era of the company in partnership with the medical community developing novel solutions for medically supervised settings talphera will begin trading on nasdaq under the trading symbol "tlph" effective january 10 san mateo, calif. , jan. 9, 2024 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the rebranding of the company, with a name change to talphera, inc. ("talphera").
2023-12-12 08:30:00 - Press Release
Acelrx Pharmaceuticals Announces Publication Of Study Evaluating Anticoagulation Practices For Continuous Renal Replacement Therapy In The United States
Use of crrt increased during covid and remained at these higher utilization levels study results demonstrate challenges physicians have with heparin and citrate, the two currently available crrt anticoagulants san mateo, calif. , dec. 12, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current u.s. physician anticoagulation use during continuous renal replacement therapy (crrt) in patients with acute kidney injury in the intensive care unit.
2023-11-08 16:05:00 - Press Release
Acelrx Reports Third Quarter 2023 Financial Results And Provides Corporate Update
Niyad™ investigational device exemption (ide) approval by the fda achieved in third quarter company plans to begin its niyad registrational study this quarter with topline data expected mid-2024 cash and investments of $13.4 million as of september 30, 2023 financing closed in july led by new healthcare investors providing up to $26.3 million, of which $10 million was made immediately available key opinion leader panel discussion on niyad planned for december 6 th webcast and conference call to be held today at 4:30 p.m. et san mateo, calif.
2023-10-26 16:30:00 - Press Release
Acelrx To Host Third Quarter 2023 Financial Results Call And Webcast On November 8, 2023
Hayward, calif. , oct. 26, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2023 financial results after market close on wednesday, november 8, 2023, then host a live webcast and conference call at 4:30 p.m.
2023-10-03 08:30:00 - Press Release
Acelrx Receives Ide Approval For Niyad And Advances To A Single Registration Study
Investigational device exemption (ide) approval by the u.s. food and drug administration (fda) allows acelrx to begin pivotal study of niyad™ single registration study with pre-agreed upon endpoints planned to initiate in q4 2023 with topline data expected mid-2024; clinical site readiness is currently underway niyad would be the first and only approved regional anticoagulant in the u.s. for the extracorporeal circuit, if approved by the fda san mateo, calif. , oct. 3, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it is advancing niyad™ (a lyophilized formulation of nafamostat) into a registrational study following the recent approval of an investigational device exemption (ide) submission to the united states food and drug administration (fda).
Latest News
2023-11-09 00:27:10 - Seeking Alpha
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Thomas Yip - H.C. Wainwright & Co. James Molloy - Alliance Global Partners Operator Welcome to the AcelRx third quarter 2023 financial results conference call.
2023-08-10 20:16:06 - Seeking Alpha
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2023 Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief Financial Officer Vince Angotti – Chief Executive Officer Pam Palmer – Founder and Chief Medical Officer Conference Call Participants Thomas Yip – H.C. Wainwright Laura Suriel – Alliance Global Operator Welcome to the AcelRx Second Quarter 2023 Financial Results Conference Call.
2023-08-10 19:01:50 - Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $1.20 per share a year ago.
2023-05-10 19:45:22 - Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.20 per share a year ago.
2023-03-30 20:28:14 - Seeking Alpha
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Welcome to the AcelRx 2022 Full Year and Fourth Quarter Financial Results Conference Call. This call is being webcast live via the Events page on the Investors section of AcelRx's website at www.acelrx.com.
2023-03-30 20:01:38 - Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-21 16:05:00 - PRNewsWire
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release full year and fourth quarter financial results for 2022 after the market close on Thursday, March 30, 2023.
2022-11-14 23:09:02 - Seeking Alpha
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Thomas Lee - HC Wainwright & Company Operator Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx's website at www.acelrx.com.
2022-11-14 18:48:36 - Zacks Investment Research
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-08-18 08:53:09 - Seeking Alpha
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
AcelRx's 2Q22 Earnings Release and Call provided little tangible news. However, it becomes more and more obvious that ACRX's management is fully shifting the focus from commercial DSUVIA to launching the Syringes products and Niyad.